Tvardi Therapeutics, Inc. (TVRD)
(Delayed Data from NSDQ)
$23.93 USD
+0.81 (3.48%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $23.46 -0.47 (-1.94%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Tvardi Therapeutics, Inc.'s return on equity, or ROE, is -710.04% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that TVRD has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TVRD 23.93 +0.81(3.48%)
Will TVRD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TVRD based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for TVRD
Tvardi Therapeutics management to meet with Piper Sandler
Tvardi Therapeutics management to meet with Piper Sandler
Upcoming Meetings for TVRD Scheduled in Boston and New York | TVRD Stock News
Tvardi Therapeutics management to meet with Piper Sandler
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference | TVRD Stock News